Luciano Adorini

机构：Intercept Pharmaceuticals (United States) · ORCID：0000-0001-8109-339X

发表论文 533 篇 · 总被引 32103 次 · h-index 89

代表论文

• Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development (2019 · Journal of Hepatology · 被引 684)
• FXR agonists in NASH treatment (2023 · Journal of Hepatology · 被引 178)
• FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid (2018 · Gastroenterology · 被引 149)
• FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice (2018 · Hepatology Communications · 被引 108)
• The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma (2019 · PLoS ONE · 被引 67)
• The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice (2022 · Journal of Biological Chemistry · 被引 63)